Vagus Nerve & Rheumatoid Arthritis: Neuroimmune Modulation Trial
Okay, here’s a breakdown of the information from the provided text, focusing on key findings related to efficacy (results) and safety:
Efficacy (Results)
* ACR20 Response: At 6 months, Arm 1 (higher stimulation) showed considerably higher ACR20 response rates compared to Arm 2 (lower stimulation). Specifically:
* Month 1: 48.1% vs. 28.3% (P = 0.0097)
* Month 2: 54.8% vs. 31.0% (P = 0.0009)
* Month 3: 57.9% vs. 34.5% (P = 0.0131)
* EULAR Good/Moderate Response: Similar to ACR20, Arm 1 had significantly higher EULAR response rates at months 1, 2, and 3.
* DAS28-CRP MCID: Arm 1 showed a higher percentage of patients achieving the MCID (Minimal Clinically Vital Difference) on the DAS28-CRP scale at months 1, 2, and 3.
* HAQ-DI MCID: Arm 1 also showed a higher percentage of patients achieving the MCID on the HAQ-DI scale at months 1, 2, and 3.
* 12-Month Follow-up (Nonresponder Imputation): Using nonresponder imputation, the ACR20 response was around 50-51% in both arms, EULAR good/moderate response was around 70-71%, DAS28-CRP MCID was 60.3% (Arm 1) and 55.8% (Arm 2), and HAQ-DI MCID was around 55% in both arms.
Safety
* No Serious Issues: No deaths or unanticipated adverse device effects were reported.
* Implantation-Related Events: Adverse events related to the implantation procedure occurred in 15.6% of patients (52 events). These were generally mild to moderate and consistent with other similar devices.
* Hoarseness/Vocal Cord Issues: The most common implantation-related events were mild to moderate hoarseness, categorized as vocal cord paresis (4.5%) or dysphonia (2.9%).These resolved over time, with some patients receiving fillers or voice therapy. No surgeries were needed.
* Surgical Site Issues: 5.4% of patients experienced mild to moderate issues at the surgical site (swelling,hypoesthesia,stitch abscess/infection,pain,erythema,suture complication).
* stimulation-Related Events: Stimulation was generally well-tolerated.
* Mild to moderate pain occurred in 4.2% of patients during the controlled period and 4.6% during long-term follow-up.
* These events typically resolved by adjusting stimulation strength or timing, without stopping therapy.
P-value Significance:
* P* < 0.025
* P < 0.01
* P* < 0.001
In essence, the study suggests that the higher stimulation arm (Arm 1) demonstrated significantly better clinical responses in the early phases of the trial (months 1-3). While the differences appeared to lessen at 12 months (with nonresponder imputation), the device was generally safe and well-tolerated.